Get the Stockscreener App
1.35
3.57%
-0.05
Acumen Pharmaceuticals Inc stock is traded at $1.35, with a volume of 89,035.
It is down -3.57% in the last 24 hours and up +21.62% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.40
Open:
$1.37
24h Volume:
89,035
Relative Volume:
0.21
Market Cap:
$81.77M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.2054
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-14.01%
1M Performance:
+21.62%
6M Performance:
-10.00%
1Y Performance:
-58.20%
1-Day Range:
$1.35
$1.39
1-Week Range:
$1.35
$1.6195
52-Week Range:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.35 | 84.80M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
How to monitor Acumen Pharmaceuticals Inc. with trend dashboardsEquity Signal Recap With Long-Term Summary - Newser
Acumen Pharmaceuticals’ Promising Alzheimer’s Study: A Potential Game-Changer? - TipRanks
How Acumen Pharmaceuticals Inc. stock performs during market volatilityPortfolio Building Plan and Summary Guide - Newser
Using economic indicators to assess Acumen Pharmaceuticals Inc. potentialPredictable Return Strategy with AI Support - Newser
When is Acumen Pharmaceuticals Inc. stock expected to show significant growthWealth Building Picks That Work - jammulinksnews.com
Why is Acumen Pharmaceuticals Inc. stock attracting strong analyst attentionAI Powered Tracker With Low Risk - jammulinksnews.com
How strong is Acumen Pharmaceuticals Inc. company’s balance sheetEntry Signal Guidance With Proven Results - jammulinksnews.com
Analyzing drawdowns of Acumen Pharmaceuticals Inc. with statistical toolsLong-Term Safety Investment Analysis Report - Newser
Using Python tools to backtest Acumen Pharmaceuticals Inc. strategiesPortfolio Review Summary with Five-Year Outlook - Newser
What makes Acumen Pharmaceuticals Inc. stock price move sharplyProfitable Trading Blueprint with Entry Zones - Newser
Has Acumen Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewStock Entry Points Based on Technicals - Newser
Acumen Pharmaceuticals Inc. Moves Into Bullish Territory Based on MACDAlpha Focused Technical Trade Signals Gain Attention - metal.it
Momentum Screeners Rank Acumen Pharmaceuticals Inc. in Top 5 TodayDaily Chart Pattern Stock Forecast Shows Bullish Setup - beatles.ru
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025 - The Manila Times
Are Bears Losing Grip on Acumen Pharmaceuticals Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
What is Acumen Pharmaceuticals Inc. company’s growth strategyAchieve rapid returns with smart investment plans - jammulinksnews.com
How does Acumen Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results - jammulinksnews.com
What institutional investors are buying Acumen Pharmaceuticals Inc. stockFree Investment Timing Strategies - jammulinksnews.com
What is the dividend policy of Acumen Pharmaceuticals Inc. stockRapidly expanding wealth - jammulinksnews.com
How many analysts rate Acumen Pharmaceuticals Inc. as a “Buy”Overwhelming financial success - jammulinksnews.com
What is the risk reward ratio of investing in Acumen Pharmaceuticals Inc. stockConsistent high-yield stocks - jammulinksnews.com
Acumen Pharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsFree Stock Selection - Newser
Is Acumen Pharmaceuticals Inc. a good long term investmentHigh-velocity capital appreciation - PrintWeekIndia
Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up - insights.citeline.com
What analysts say about Acumen Pharmaceuticals Inc. stockMarket-beating returns - PrintWeekIndia
Is Acumen Pharmaceuticals Inc. stock overhyped or has real potentialAccelerated profit realization - jammulinksnews.com
How high can Acumen Pharmaceuticals Inc. stock price go in 2025Free Daily Trading Room Entry - jammulinksnews.com
Does Acumen Pharmaceuticals Inc. stock pay reliable dividendsSuperior capital gains - jammulinksnews.com
Acumen Pharmaceuticals shares rise 2.92% after-hours following European Commission approval of DARZALEX Faspro® for multiple myeloma. - AInvest
Is RNST a good long term investmentRapid-fire capital growth - Autocar Professional
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):